We assessed the effect of stage, grade, and histologic type on cancer-specific mortality after surgery in candidates for 1 of the 4 North American ongoing immune-oncology checkpoint inhibitor trials. Important differences exist in the inclusion criteria among the 4 ongoing adjuvant trials. By generating 4 random samples, we have demonstrated that the differences in the inclusion criteria are reflected in the differences in the mortality rates.
A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality
Mazzone E.;Briganti A.;
2020-01-01
Abstract
We assessed the effect of stage, grade, and histologic type on cancer-specific mortality after surgery in candidates for 1 of the 4 North American ongoing immune-oncology checkpoint inhibitor trials. Important differences exist in the inclusion criteria among the 4 ongoing adjuvant trials. By generating 4 random samples, we have demonstrated that the differences in the inclusion criteria are reflected in the differences in the mortality rates.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
